CoreAge Rx
PartnerThe most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, no pay-to-win placement.
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxA polished, high-disclosure compounded program with strong nationwide coverage.
Visit EdenCoreAge Rx takes it with a higher Verdict Score — 94/100 to 91/100 (grade A vs A−). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Eden still earns its place — people who prioritize a vetted, high-transparency provider over the lowest sticker price.
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
| Metric | CoreAge Rx | Eden |
|---|---|---|
| Verdict Score | 94/100 | 91/100 |
| Grade | A | A− |
| Semaglutide | $149/mo | $239/mo |
| Tirzepatide | $349/mo | $349/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | No | No |
| Relationship | Partner | Partner |
What we like
The caveats
What we like
The caveats
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
People who prioritize a vetted, high-transparency provider over the lowest sticker price.
Visit Eden Read the full Eden review →Or browse the full comparison hub and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.